Vancouver, British Columbia – (March 2, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has granted 2,100,000 incentive stock options under the Company’s Stock Option Plan (“Option Plan”) to third-party consultants to support market communication and corporate strategy as it advances its commercialization efforts. Each option is exercisable into one common share at a price of $0.25 per share and will vest immediately. The options will expire two years from the date of grant. All other terms and conditions of options are in accordance with the terms of the Company’s Stock Option Plan.

In addition, BioMark has cancelled 100,000 options previously issued to consultants.

Press Release – BioMark Grants Options


Vancouver, British Columbia – (February 16, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. has entered into a collaborative research and development agreement with Phytronix Technologies Inc. (“Phytronix”) to advance the development of BioMark’s early lung cancer screening applications using Phytronix-proprietary Laser Diode Thermal Desorption (LDTD) technology. While BioMark Diagnostic Solutions is preparing to offer lab services and metabolomics capabilities in Quebec City to accelerate commercialization of its assays, the Quebec-based Phytronix will bring its experience in high-throughput analysis, automated sample preparation and assay development to this collaboration.


“BioMark and Phytronix have been working on developing internal standards for BioMark’s acetyl-amantadine assay. The group intends to widen the scope of the partnership to include the development of an ultra high-throughput technique, using the LDTD-based Luxon-MS/MS system, for lung cancer screening applications and establish new standards to further increase the sensitivity of the assay,” says BioMark CEO, Rashid Bux. “Ultimately, the increased sensitivity can help determine better sub-types of lung cancer as well as increasing the robustness and the speed of the assay. As the sole maker of this mass-spectrometry-based instrumentation in Canada, Phytronix will assist with sourcing the Luxon Ion Source®-system along with automated sample preparation.”


Thanks to the expertise it has developed for more than 20 years, Phytronix will support BioMark’s team in setting up a state-of-the art clinical lab services in Quebec City and perform technical training on the Luxon-MS/MS system. Phytronix’s technical capabilities in instrumentation, support, and service are an important part of the clinical laboratory infrastructure BioMark Diagnostic Solutions is building in Quebec City. Both companies intend to demonstrate the uniqueness of the technology by showcasing it later in 2021, through a sponsored research program.


“In addition, Phytronix’s installed base within CLIA-certified labs in the U.S. could be an important driver for the adoption of BioMark’s early lung cancer screening assay across North America and other global markets. We are delighted to collaborate with Phytronix’s excellent team and their leading-edge technology platform,” Mr. Bux added.



About Phytronix Technologies Inc.


Phytronix Technologies Inc. is a privately-owned company based in Québec City, Canada, and was founded in 2000. Phytronix invented and patented the Laser Diode Thermal Desorption (LDTD) technology for mass spectrometry. The company introduced the Luxon Ion Source®, which is the second-generation apparatus based on the patented-LDTD® technology and currently the fastest technology for mass spectrometry. This innovative technology enables ultra-high-speed analysis in less than 4 seconds per sample. The company will provide the optimized internal standards that are necessary for use in clinical settings, along with technical expertise required with high-throughput mass spectrometry.





Vancouver, British Columbia – (February 8, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Use of Amantadine in the Evaluation of Response to Chemotherapy in Lung Cancer – a Pilot Study” has been published in the peer-reviewed journal Future Science OA.

Rashid A. Bux, President and CEO of BioMark, says, “This publication shows the potential of our liquid biopsy platform’s ability to provide a novel and low-cost test to quickly assess a patient’s response to cancer treatment so that clinicians can adjust the treatment regimen accordingly. The present pilot study tested the hypothesis that SSAT-1 activity within the tumor, as measured by plasma acetylamantadine concentrations, can be used to monitor patient response to therapy.  In this preliminary study and interim analysis, a reduction in the plasma concentration of acetylamantadine was associated with disease remission subsequent to initial chemotherapy in patients diagnosed with stage III lung cancer. This could be used as a simple and effective test to assess response to treatment and to better tailor treatment of the patient as well as reducing side-effects and costs.”

The paper is available through open access at

BioMark encourages subscription to Future Science for individuals and institutions interested in keeping abreast of new developments in biotechnology and medicine.

This study is the result of a pan-Canadian initiative to identify biomarkers that detect cancer and monitor response to treatment and is also the first to report the ability to detect and quantify plasma concentrations of acetylamantadine in lung cancer patient. BioMark would like to acknowledge and thank the clinicians and the scientific team involved in this study and for their continued support in developing yet another application of its SSAT amantadine assay. BioMark’s clinical and scientific team plans to conduct a larger trial at other clinical sites in 2021 based on the outcome of this pilot study.


Clinical Application

During the first few months of lung cancer treatment, the standard monitoring therapeutic efficacy consisting of serial CT scans may not provide clear clinical guidance. Misinterpretation of scans can lead to inappropriate discontinuation of a potentially effective therapy; conversely, an ineffective treatment could be continued hoping for a delayed response that may never come. From a clinical perspective, the development of a reliable test that can assess the effects of chemotherapy and can be performed earlier in the treatment cycle would be highly beneficial as it would avoid prolonged use and toxicity in patients and thus assist in the decision to modify the treatment regimen.  Furthermore, assessing response early means security in knowing that the treatment is having the desired effect.  Alternatively, early evidence of lack of response allows transition to second-line options for systemic therapy which could then be initiated without delay.  Delays in transitioning treatment means a greater burden of disease and reduced ability of patients to tolerate second-line systemic therapy. Thus, researchers, clinicians and experts within the field need to direct their attention to identify reliable, reproducible, and cost-effective measures to evaluate response to chemotherapy that can be implemented worldwide.


World Cancer Day

BioMark salutes all those involved in observing the annual World Cancer Day that was born on the 4 February 2000 at the World Summit Against Cancer for the New Millennium in Paris. The Paris Charter aims to promote research, prevent cancer, improve patient services, raise awareness and mobilize the global community to make progress against cancer, and includes the adoption of World Cancer Day. February 4 is World Cancer Day, an opportunity to unite globally in the effort to end the injustice of preventable suffering from cancer by raising awareness of the patient experience, the need for accessible and equal access to treatment, and working towards cures. We at BioMark aspire to provide leading edge early diagnostic and monitoring of response to treatment that enables better cancer care management.


About Future Science OA

Launched in March 2015, Future Science OA is the inaugural gold open access journal from Future Science Group. It publishes articles covering research of application to human health and utilizes a CC-BY license. Future Science OA embraces the importance of publishing all good-quality research with the potential to further the progress of medical science. Negative and early-phase research will be considered. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis.


About Future Science Group

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG’s portfolio includes two imprints, Future Science and Future Medicine. Both publish eBooks and journals. In addition to this core publishing business FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine. The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.

For all queries, contact Laura Dormer email to:


Alfred Berkeley Joins BioMark’s Advisory Team

Vancouver, British Columbia – (January 11, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is glad to announce Alfred Berkeley as a new member of the BioMark’s Advisory team as he will be providing strategic and financial advice to help expand the company’s commercialization effort in the U.S.


Mr. Rashid Ahmed Bux, CEO and President of BioMark Diagnostics says: “We are extremely proud and honored to have Mr. Berkeley join our advisory group at this moment. Mr. Berkeley brings years of experience and a deep knowledge of both financial and business development activities in the U.S. His past support and continued counsel are greatly appreciated, and his extensive experience and connections will be invaluable as BioMark moves to make a committed effort to instigate commercialization and expand its clinical research collaborations in the U.S.”

BioMark’s board and shareholders welcome Mr. Berkeley and look forward to his professional contribution to building BioMark into a stronger international entity with an operating base in North America.


About Alfred Rives Berkeley III


Mr. Alfred Rives Berkeley, III, has over 40 years of experience in the financial industry, and currently serves as the Chairman at Princeton Capital Management, Inc., since January 2013, a position he previously held from 1996 to 2006. He currently serves as Chairman of the Board at Noxilizer, Inc., and has been a Director of RealPage, Inc since 2003. He is also a member of the Board of Visitors of the School of Medicine of the University of Maryland and has served as a Trustee of the Johns Hopkins University, the Nature Conservancy, and the Mathematical Sciences Research Institute.

Mr Berkeley started his career by joining Alex Brown & Sons in 1972 as a Research Analyst, and became General Partner there in 1983, Head of Information Services in 1985, moved on to the Merger and Acquisition department in 1987, and became Managing Director and Senior Banker in the Corporate Finance. Between 1996 and 2000, Mr. Berkeley was President of the NASDAQ Stock Market, Inc., after which he was named Vice-Chairman until 2003.

Mr. Berkeley has also served as a member of numerous government advisory panels including The President’s National Infrastructure Advisory Council and the Monetary Authority of Singapore’s International Advisory Council. He was appointed to the National Infrastructure Assurance Council by President George W. Bush.

He has also been a Director of a number of public and private companies, institutions, and non-profit organizations including Policy Management Systems, Comshare, Cognos, ACI Worldwide, Edgar Online, Noxilizer, Inc., Security First Corp., Gentag, Inc., ViiNet, Inc., Differential Dynamics, Inc., The Nature Conservancy, WebEx Communication, Inc., Policy Management Systems Corporation, The World Economic Forum USA, and Johns Hopkins University.

Mr. Berkeley has served as Captain in the US Air Force from 1968 to 1972 and officer in the US Air Force Reserve and earned his M.B.A. from the Wharton School and a BA in English from the University of Virginia.

Press Release – Alfred Berkeley Joins BioMark’s Advisory Team